Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma

Oncology (Switzerland)

Volumn 83, Issue 6, 2012, Pages 339-345

  Carr, Brian I ^a   Guerra, Vito ^b   Pancoska, Petr ^c  

^a Departments of Nutritional Carcinogenesis   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Fetoprotein; Glutamyl transpeptidase; Diameter; Hepatocellular carcinoma; Portal vein thrombosis; Thrombocytopenia

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR BIOPSY; TUMOR VOLUME;

ALKALINE PHOSPHATASE; ALPHA-FETOPROTEINS; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; HYPERTENSION, PORTAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 84866483427     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342431     Document Type: Article

References (13)

1. Bosch FX, Ribes J, Diaz M, et al: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16.
2. Vernook, AP, Papandreou C, Furuse J, de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15(suppl 4):5-13.
3. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985; 56: 918-928.
4. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer 1989; 64: 1700-1707.
5. Peng SY, Chen WJ, Lai PL, et al: High alphafetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004; 112: 44-50.
6. Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA: Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol 2008; 23: 1259-1266.
7. Pancoska P, Carr BI, Branch RA: Networkbased analysis of survival for unresectable hepatocellular carcinoma. Semin Oncol 2010; 37: 170-181.
8. Carr BI, Pancoska P, Branch RA: Low alphafetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol 2010; 25: 1543-1549.
9. Carr BI, Pancoska P, Branch RA: HCC in young adults. Hepatogastroenterology 2010; 57: 436-440.
10. Carr BI, Lu SN, Pancoska P: Small hepatocellular carcinoma in Chinese patients. Hepatogastroenterology 2011; 58: 1334-1342.
11. Lu SN, Wang JH, Liu SL, et al: Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107: 2212-2222.
12. Kawamura Y, Arase Y, Ikeda K, et al: Largescale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107: 253-261.
13. Huang YC, Huang CF, Chang KC, et al: Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B-and C-endemic area. J Gastroenterol Hepatol 2011; 26: 129-134.